A prognostic 3‐long noncoding RNA signature for patients with gastric cancer

Abstract

Current studies showed that long noncoding RNAs (lncRNAs) may act as prognostic biomarkers in a variety of cancers. The aim of this study was to identify and assess a prognostic lncRNA signature in patients with gastric carcinoma (GC). LncRNAs expression profiles and corresponding clinicopathological data for 350 patients with GC were obtained from The Cancer Genome Atlas (TCGA), and the least absolute shrinkage and selection operator Cox (LASSO Cox) regression model was used to identify the lncRNA signature. Finally, 3 lncRNAs (CYP4A22-AS1, AP000695.6, and RP11-108M12.3) were identified using LASSO Cox. The prognostic score was imputed as follows: (0.354 × expression level of AP000695.6) + (- 0.899 × expression level of CYP4A22-AS1) + (0.881 × expression level of RP11-108M12.3). The nomogram that integrated independent prognostic factors (age, American Joint Committee on Cancer-lymph node status, and residual tumor and risk score) was constructed. In TCGA cohort, the area under the curve (AUC) for the predictive nomogram was 0.737 (19-month survival). The calibration curve also demonstrated satisfactory agreement between predictive values and observation values in the probabilities of 1-, 3-, and 5-year overall survival. We also established prognostic model using machine learning technique, and the corresponding AUC for the predictive model was 0.756 (19-month survival). The Kyoto Encyclopedia of Genes and Genomes pathway analysis showed that the Hippo signaling pathway was the main pathway associated with the 3-lncRNA signature.

The competitive endogenous RNA regulatory network reveals potential prognostic biomarkers for overall survival in hepatocellular carcinoma

“…The nomogram, as a graphical display tool, was convenient to calculate and interpret the predictive results . Therefore the aim of the present study is to develop and validate a prognostic nomogram for OS of HCC patients based on gene expression data identified by a ceRNA regulatory network.…”

Long noncoding RNA SNHG17 induced by YY1 facilitates the glioma progression through targeting miR-506-3p/CTNNB1 axis to activate Wnt/β-catenin signaling pathway

“…LncRNA MALAT1 was reported to have malignant status and predicted poor prognosis in glioma [23]. LncRNA SNHG17 was validated to promote the progression of NSCLC and gastric cancer [24,25]. In present study, SNHG17 expression was identified to be elevated in glioma tissues and cell lines.…”

Long non-coding RNASNHG17 promotes the progression of breast cancer by sponging miR-124-3p

“…Aberrant expression of SNHG17 has been reported to play oncogenic role in several cancers by regulating cancer cell proliferation, migration and metastasis [11][12][13]26]. However, the role of SNHG17 in BC is not well known.…”